Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients


Primary Objectives:To evaluate the safety and tolerability of the combination of isatuximab (also known as SAR650984) and cemiplimab (also known as REGN2810) in patients with relapse/refractory multiple myeloma. - To compare the overall response of the combination of isatuximab and cemiplimab versus isatuximab alone in patients with RRMM based on International Myeloma Working Group (IMWG) criteria.

Secondary Objectives: To evaluate the efficacy as assessed by clinical benefit rate (CBR), duration of response (DOR), time to response (TTR), progression free survival (PFS), and overall survival (OS). - To assess the pharmacokinetics (PK) of isatuximab and cemiplimab when given in combination. - To assess the immunogenicity of isatuximab and cemiplimab when given in combination.

The duration of the study for a patient will include a period for screening of up to 21 days and 3-month post treatment follow up. The cycle duration is 28 days. Patients will continue treatment until disease progression, unacceptable adverse events, consent withdrawal, or any other reason.

SparkCures ID 973
Trial Phase Phase 1/2
Enrollment 105 Patients
Trial Sponsors
  • Sanofi
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion criteria:

  • Patients must have a known diagnosis of multiple myeloma with evidence of measurable disease, as defined below:
    • Serum M-protein ≥ 1 g/dL (≥ 0.5 g/dL in case of immunoglobulin A [IgA] disease), AND/OR
    • Urine M-protein ≥ 200 mg/24 hours, OR
    • In the absence of measurable M-protein, serum immunoglobulin free light chain ≥ 10 mg/dL, and abnormal serum immunoglobulin kappa lambda free light chain ratio (< 0.26 or > 1.65).
  • Patients must have received prior treatment with an immunomodulatory drug (IMiD) (for ≥ 2 cycles or ≥ 2 months of treatment) and a proteasome inhibitor (PI) (for ≥ 2 cycles or ≥ 2 months of treatment).
  • Patients must have received at least 3 prior lines of therapy (Note: Induction therapy and stem cell transplant ± maintenance will be considered as one line).
  • Patient must have achieved MR or better with any anti-myeloma therapy (ie, primary refractory disease is not eligible).

Exclusion criteria:

  • Prior exposure to isatuximab or participated clinical studies with isatuximab.
  • Prior exposure to any agent (approved or investigational) that blocks the programmed cell death-1 (PD-1)/PD-L1 pathway.
  • Evidence of other immune related disease/conditions.
  • History of non-infectious pneumonitis requiring steroids or current pneumonitis; history of the thoracic radiation.
  • Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
  • Has allogenic haemopoietic stem cell (HSC) transplant.
  • Prior treatment with idelalisib (a PI3K inhibitor).
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) >2.
  • Poor bone marrow reserve.
  • Poor organ function.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

US Trial Locations

Please visit the page for historical site information.

View Centers